Why the study?
Does blockade of the AGEs/HMGB-1-RAGE system prevent cardiovascular disease in patients with diabetes or age-related CVD?
Population
Patients with diabetes and/or age-related cardiovascular disease, and animal models
Design
Review
Authors
Loading...
Hypothesis-generating for RAGE blockade in diabetes- and age-related CVD; randomized trials needed before clinical adoption.
Does blockade of the AGEs/HMGB-1-RAGE system prevent cardiovascular disease in patients with diabetes or age-related CVD?
The AGEs/HMGB-1-RAGE system plays a central role in the pathogenesis of cardiovascular disease, highlighting its potential as a therapeutic target for preventing diabetes- and age-related CVD.
Fukami et al. (2014) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: